CalciMedica Inc.

NASDAQ: CALC · Real-Time Price · USD
1.52
0.01 (0.66%)
At close: Apr 29, 2025, 3:54 PM
1.54
1.32%
After-hours: Apr 29, 2025, 03:54 PM EDT
0.66%
Bid 1.51
Market Cap 20.49M
Revenue (ttm) n/a
Net Income (ttm) -13.7M
EPS (ttm) -1.22
PE Ratio (ttm) -1.25
Forward PE -0.83
Analyst Buy
Ask 1.69
Volume 6,864
Avg. Volume (20D) 41,401
Open 1.53
Previous Close 1.51
Day's Range 1.52 - 1.56
52-Week Range 1.43 - 6.26
Beta 1.11

About CALC

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC c...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 14, 2023
Employees 14
Stock Exchange NASDAQ
Ticker Symbol CALC
Full Company Profile

Advertisement

Analyst Forecast

According to 3 analyst ratings, the average rating for CALC stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 952.63% from the latest price.

Stock Forecasts
1 month ago
-6.17%
CalciMedica shares are trading lower. The company ... Unlock content with Pro Subscription
6 months ago
-22.92%
CalciMedica shares are trading lower after the company announced a $10.2 million common stock offering.